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Abstract 
Background: Plasmodium ovale is rarely described in Senegal. A case of clinical malaria due to P. ovale wallikeri in 
West Central of Senegal is reported.
Case: A 34-year-old male baker in Dakar, with no significant previous medical history, was admitted to a health 
clinic with fever and vomiting. Fever had been lasting for 4 days with peaks every 48 h. As monospecific Plasmodium 
falciparum HRP-2 RDT was negative, he was treated with antibiotics. However, owing to persisting symptoms, he was 
referred to the emergency unit of the Youssou Mbargane Diop Hospital, Dakar, Senegal. Clinical examination found 
impaired general condition. All other physical examinations were normal. Laboratory tests showed anaemia (haemo-
globin 11.4 g/dl), severe thrombocytopaenia (platelets 30 × 109/mm3), leukopenia (3650/mm3), lymphocytopenia 
(650/mm3). Renal function was normal as indicated by creatininaemia and uraemia (11 mg/l and 0.25 g/l, respectively) 
and liver enzymes were slightly elevated (aspartate aminotransferase 77 UI/l and alanine aminotransferase 82 UI/l). 
Blood smear evaluations in Parasitology Laboratory of Aristide Le Dantec Hospital showed malaria parasites of the 
species P. ovale with a 0.08 % parasitaemia. Molecular confirmation was done by real time PCR targeting the 18S rRNA 
gene. The P. ovale infection was further analysed to species level targeting the potra gene and was identified as P. ovale 
wallikeri. According to the hospital’s malaria treatment guidelines for severe malaria, treatment consisted of intrave-
nous quinine at hour 0 (start of treatment) and 24 h after initial treatment, followed by artemether–lumefantrine 24 h 
later. A negative microscopy was noted on day 3 post-treatment and the patient reported no further symptoms.
Conclusion: Malaria due to non-falciparum species is probably underestimated in Senegal. RDTs specific to non-fal-
ciparum species and/or pan specific RDTs should be included as tools of diagnosis to fight against malaria in Senegal. 
In addition, a field-deployable molecular tool such as the loop-mediated isothermal amplification can be considered 
as an additional useful tool to detect low malaria parasite infections and for speciation. In addition, national malaria 
control policies should consider other non-falciparum species in treatment guidelines, including the provision of 
primaquine for the treatment of relapsing parasites.
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Background
Despite the fact that Plasmodium ovale is endemic in 
tropical Africa, malaria due to P. ovale is rarely described 
in Senegal [1]. The most common pathogen of malaria 
in Africa is Plasmodium falciparum [2]. In the 1990s, 
P. ovale infections were described in the south of Sen-
egal in the context of the longitudinal study at Dielmo 
village located 280  km South East of Dakar [1]. During 
the first year of the project in 1990, the prevalence of P. 
ovale was determined, among symptomatic and asymp-
tomatic villagers of all groups age, to be 5.5 % either as a 
mono-infection or as mixed infection with P. falciparum 
[3]. Concerted efforts to control malaria in Senegal con-
tributed to decrease in the overall prevalence of malaria 
and by 2010 P. ovale infections were rarely reported [1]. 
Recently, a molecular survey found P. ovale in Kedougou 
only as mixed infections with P. falciparum at 11.5 % of 
prevalence [4].
Plasmodium ovale consists of two distinct species: P. 
ovale curtisi (classic type) and P. ovale wallikeri (vari-
ant type) [5]. The two species are indistinguishable by 
microscopy but seem to differ in their duration of latency 
[6]. The recent description of dimorphism in the gene 
encoding P. ovale tryptophan-rich antigen (potra) allows 
for the distinction between the two P. ovale species. 
Sequence and size variations were noted between the 
tryptophan-rich antigen genes from P. ovale curtisi (poc-
tra) and P. ovale wallikeri (powtra) [5]. This was exploited 
in a nested PCR detection assay [7], where the species 
are discriminated by the size of the amplified fragments 
(299 or 317  bp for poctra; 245  bp for powtra). In addi-
tion, Tanomsing et  al. developed a semi-nested PCR 
protocol which efficiently discriminate P. ovale wallikeri 
and P. ovale curtisi and found that the 299 bp fragment 
was overlapping between the two subspecies [8] and the 
245 bp, represented P. ovale wallikeri.
A case of malaria due to P. ovale wallikeri is described 
in a patient admitted to the emergency unit service of the 
Youssou Mbargane Diop Hospital of Rufisque, a depart-
ment of the peripheral region of Dakar in Senegal.
Case presentation
A 34-year-old male baker living in Diamniadio (Dakar 
region) sought a consultation at a health centre near his 
home for fever, headache, vomiting and diarrhoea. Fever 
had lasted for 4 days with peaks every 48 h. The patient 
was suspected of malaria and was tested using an HRP-2 
based RDT (detecting only P. falciparum). The test was 
negative for P. falciparum malaria and the patient was 
treated by three intravenous (IV) injection of cefotaxim 
(third generation of cephalosporin) at 100  mg per kg 
per day to cover potential bacterial infection. Owing to 
persisting symptoms 4 days later, he was referred to the 
emergency unit of the Youssou Mbargane Diop Hospital, 
Dakar, Senegal.
The patient had no particular previous medical history. 
He was born in Thies and moved to Touba at the age 12 
and finally at age 23 to Diamniadio, where he has lived 
since. The patient claimed that he had never been out of 
these three areas, which are all in West Central of Sen-
egal. Physical examination found impaired general condi-
tion but the patient was conscious. Abdomen was tender. 
All other physical examinations were normal. Another 
HRP-2 based RDT was performed and was also negative. 
Other laboratory tests showed anaemia (haemoglobin 
11.4 g/dl), thrombocytopaenia (platelets 30 × 109/mm3), 
leukopaenia (3650/mm3) and lymphocytopaenia (650/
mm3). Kidney function was normal as indicated by cre-
atininaemia and uraemia (11  mg/l and 0.13  g/l, respec-
tively). Transaminases were slightly elevated.
Blood smear evaluations in the Parasitology Laboratory 
of Aristide Le Dantec University Hospital showed malaria 
parasites in normal and enlarged red blood cells (RBCs). 
Some infected RBCs were oval shaped and some were 
fimbriated. However, Schüffner’s dots were not observed 
likely due to staining defect (Fig. 1). All malaria parasite 
stages (rings, trophozoites, schizonts and gametocytes) 
were observed. These malaria parasites were identified as 
P. ovale and a 0.08 % parasitaemia was calculated. Para-
site density was measured by determining the ratio of 
parasites/leucocytes on the basis of 8000 leucocytes/μl 
after counting 500 leucocytes. That ratio was found to be 
1.1 giving a parasite density of 8800 parasites/μl of blood.
An 18S rRNA gene real-time PCR molecular assay was 
undertaken as previously described [9] to confirm the 
P. ovale, infection (Fig. 2). No others species of Plasmo-
dium was detected. The parasite was then subtyped using 
the potra gene as target as previously described [7]. This 
genotyping identified the presence of P. ovale wallikeri 
(Fig. 3).
Based on clinical signs and biological findings, the 
patient was treated as severe malaria accordingly to the 
hospital’s treatment guideline. Intravenous quinine was 
given at admission and 24 h later. 48 h after initial treat-
ment, oral artemether–lumefantrine was given every 6 h 
at six doses. On day 3 after treatment, microscopy was 
negative and the patient reported no further symptoms. 
Primaquine was not given (see “Discussion” section).
Discussion
Plasmodium ovale is a malaria parasite that is endemic 
in sub-Saharan Africa, although not very commonly 
described [2]. In Senegal, little attention has been paid to 
P. ovale malaria in the recent years. Here, a case of P. ovale 
infection that appears to have been acquired in Diamnia-
dio, near Dakar, in West Central of Senegal is reported. 
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This case highlights the need to consider non-falciparum 
malaria infections in this region for case management. 
Plasmodium ovale malaria is often mild in clinical pres-
entation [10] and severe forms of the disease are rela-
tively rare [11–13]. The parasite densities are often less 
than 50 parasites/μl and a parasitaemia higher than 5000 
parasites/μl is rarely reported [14]. This is believed to be 
due to the fact that P. ovale prefers younger RBCs, which 
are rare in peripheral blood [2]. The patient in this report 
presented a relatively high density parasitaemia of 8800 
parasites/μl and severe thrombocytopaenia. Equally 
high parasitaemia levels were found in Spanish travel-
lers infected with P. ovale wallikeri imported from dif-
ferent countries in Africa and the same study observed 
that severe thrombocytopaenia was more commonly 
associated with P. ovale wallikeri infection than with P. 
ovale curtisi infections [15]. While the mechanisms that 
produce thrombocytopaenia in malaria is still not clear it 
seems likely to be linked to a greater severity of the illness 
[16].
In Senegal, P. ovale subtyping is not documented. 
Determining the infecting P. ovale species may be 
important because recent observations suggest that the 
two species might differ in their relapsing patterns [6] 
and secondly. Plasmodium ovale wallikeri seems to be 
slightly more pathogenic [15]. The previously described 
dimorphisms observed in gene encoding P. ovale tryp-
tophan-rich antigen (potra) [5] were used to identify the 
infecting P. ovale species as P. ovale wallikeri. This is most 
likely the first time P. ovale species determination have 
been undertaken when describing P. ovale infections in 
Dakar, Senegal.
The patient in this study denied having travelled outside 
Diamniadio suggesting that the P. ovale infection was likely 
acquired locally. Since Diamniadio is a  crossroads town 
located at the town exit of Dakar where many different 
human populations from neighbouring regions and coun-
tries intersect there are two possible likely sources of the P. 
ovale parasites: (1) from an existing P. ovale reservoir in or 
near Diamniadio, or (2) that the source of the P. ovale infec-
tion came from another region or neighbouring countries. 
In the 1990s, in a study in Dielmo, exposure to P. ovale was 
reported across all ages and perennial transmission of P. fal-
ciparum was also noted [17], therefore, it is possible that P. 
Fig. 1 Giemsa-stained thin blood smears Plasmodium ovale trophozoites in enlarged and ovale shaped red blood cell (a) and with a fimbriated red 
blood cell (b–d)
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falciparum cross immunity could protect against non-falci-
parum species [2]. However, in the West Central of Senegal 
like Diamniadio where malaria transmission is very low, 
this cross immunity might be low or none existing, making 
it easy to acquire malaria, including non-falciparum infec-
tions, as in this case report.
This present findings highlight the need to consider 
non-falciparum malaria infections in clinical settings 
both for the appropriate treatment of the infection and 
in order to further understand the epidemiology of 
malaria in the country. Plasmodium ovale infections 
present unique challenges because of the reported long 
latency period and the fact that two distinct species are 
known to exist [8]. In fact, the commonly used diagnostic 
tools in many endemic malaria regions, microscopy and 
RDT, are less sensitive when parasitaemia is very low and 
need expert microscopists or molecular assays to recog-
nize uncommon species. In Senegal, P. falciparum is the 
most prevalent parasite detected when patients are sus-
pected of malaria. Because of this, the national malaria 
control programme provides all health clinics of the 
country with HRP-2 based RDT, which are specific to P. 
falciparum. Therefore, it is possible that many cases of 
non-falciparum malaria infections are just not detected. 
This case report highlights the urgent need to develop 
standardized protocols capable of detecting all Plasmo-
dium parasites in Senegal in order to achieve the malaria 
elimination agenda. In addition, although the existence of 
P. ovale hypnozoite remain controversial [18], they pose 
an important challenge in that they can cause relapse 
malaria which has great implications for treatment and 
transmission. Therefore, more species specific RDTs and 
field-usable molecular tools, such as the loop-mediated 
isothermal amplification (LAMP) are needed to assess 
the actual prevalence of P. ovale and other non-falcipa-
rum malaria parasites in Senegal and in other parts of 
Africa as previously suggested [19].
The current World Health Organization treatment 
guidelines recommend intravenous (IV) artesunate for the 
treatment of severe malaria due to all Plasmodium species 
[20]. In Senegal, since the national malaria control policies 
targets especially P. falciparum, ACT and quinine are the 
recommended and registered anti-malarials. The patient 
discussed in this case report was treated using IV quinine 
Fig. 2 Amplification plots for the real-time PCR targeting Plasmodium species 18S rRNA. P patient sample, PC positive control (know P. ovale sample)
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followed by oral ACT, which according to the current Sen-
egalese treatment guidelines, is still the treatment of choice 
for severe malaria in adult patients [21]. ACT has shown 
high efficacy in the treatment of non-falciparum malaria 
[22]. However, a recent longitudinal study conducted in 
Uganda using real-time PCR demonstrates persistence 
of infections of both P. falciparum and non-falciparum 
infections after ACT [19]. Importantly, primaquine, which 
is effective in the killing of both gametocytes and hypno-
zoites, is currently not registered in Senegal. Availability 
of primaquine in the health facilities will help to provide 
curative treatment for hypnozoites in P. ovale infected 
patients. Currently, the national malaria control pro-
gramme plans to evaluate primaquine in the north of the 
country in an effort to end malaria in this region [21]. Also, 
chloroquine, which is the standard treatment of uncom-
plicated non-falciparum malaria, is no longer available 
in Senegal. In fact, since P. falciparum was considered 
resistant to chloroquine, this drug was withdrawn and 
national malaria control programme did not define treat-
ment guideline for non-falciparum malaria explaining how 
neglected was the non-falciparum species in Senegal [21].
Conclusion
In summary, this case report demonstrates that P. ovale 
exists in West Central of Senegal and the prevalence is 
likely to be underestimated due to the diagnostic tools in 
place.
This case also highlights the fact that P. ovale malaria is 
not as benign as previously thought and that it is impor-
tant to consider other non-falciparum malaria infections 
for appropriate patient care and for the success of the 
malaria control programme.
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